Patents by Inventor Per Borgström

Per Borgström has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7718428
    Abstract: The identification of the HYAL1 hyaluronidase enzyme as a human plasma-derived myeloid colony-stimulating factor (CSF), designated CSF5-hyaluronidase, its recombinant production and methods of use are described. This protein may be used for the treatment of myelosuppression as may occur after irradiation, chemotherapy or other diseases where an increase in leukocyte levels may be beneficial. For example, CSF5-hyaluronidase may be used to enhance the immune response to viral infection or other diseases associated with immune suppression.
    Type: Grant
    Filed: May 9, 2006
    Date of Patent: May 18, 2010
    Assignee: Halozyme, Inc.
    Inventors: Gregory I. Frost, Per Borgstrom
  • Publication number: 20090215722
    Abstract: Methods to prevent the rejection of immunogenic tissues in an animal by administering a non-immunogenic, poorly catabolized molecule in an amount sufficient to inhibit an immune response are described herein. Also described are compositions that are useful for inhibiting immune responses in animals that are recipients of cellular transplants. For example, these methods and compositions can be used to prevent the rejection of xenografted and allografted tissues in an animal.
    Type: Application
    Filed: May 8, 2009
    Publication date: August 27, 2009
    Inventors: Gregory I. Frost, Per Borgstrom
  • Patent number: 7538097
    Abstract: Methods to prevent the rejection of immunogenic tissues in an animal by administering a non-immunogenic, poorly catabolized molecule in an amount sufficient to inhibit an immune response are described herein. Also described are compositions that are useful for inhibiting immune responses in animals that are recipients of cellular transplants. For example, these methods and compositions can be used to prevent the rejection of xenografted and allografted tissues in an animal.
    Type: Grant
    Filed: September 25, 2001
    Date of Patent: May 26, 2009
    Assignees: Halozyme, Inc., Sidney Kimmel Cancer Center
    Inventors: Gregory I. Frost, Per Borgstrom
  • Publication number: 20060247201
    Abstract: The identification of the HYAL1 hyaluronidase enzyme as a human plasma-derived myeloid colony-stimulating factor (CSF), herein designated CSF5-hyaluronidase, its recombinant production and methods of use are described. This protein may be used for the treatment of myelosuppression as may occur after irradiation, chemotherapy or other diseases where an increase in leukocyte levels may be beneficial. For example, CSF5- may be used to enhance the immune response to viral infection or other diseases associated with immune suppression.
    Type: Application
    Filed: May 9, 2006
    Publication date: November 2, 2006
    Inventors: Gregory Frost, Per Borgstrom
  • Publication number: 20040047874
    Abstract: Methods to prevent the rejection of immunogenic tissues in an animal by administering a non-immunogenic, poorly catabolized molecule in an amount sufficient to inhibit an immune response are described herein. Also described are compositions that are useful for inhibiting immune responses in animals that are recipients of celular transplants. For example, these methods and compositions can be used to prevent the rejection of xenografted and allografted tissues in an animal.
    Type: Application
    Filed: October 8, 2003
    Publication date: March 11, 2004
    Inventors: Gregory I. Frost, Per Borgstrom
  • Publication number: 20030212021
    Abstract: The identification of the HYAL1 hyaluronidase enzyme as a human plasma-derived myeloid colony-stimulating factor (CSF), herein designated CSF5-hyaluronidase, its recombinant production and methods of use are described. This protein may be used for the treatment of myelosuppression as may occur after irradiation, chemotherapy or other diseases where an increase in leukocyte levels may be beneficial. For example, CSF5 may be used to enhance the immune response to viral infection or other diseases associated with immune suppression.
    Type: Application
    Filed: November 26, 2002
    Publication date: November 13, 2003
    Inventors: Gregory I. Frost, Per Borgstrom